Vernalis plc
 | |
| Public company | |
| Traded as | LSE: VER |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Winnersh, United Kingdom |
Key people |
Ian Garland (CEO) Peter Fellner (Non-Executive chairman) |
| Products | Frovatriptan, Tuzistra XR |
Number of employees | 100 |
| Website | vernalis.com |
Vernalis plc is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has two approved products; Tuzistra™ XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement with Tris Pharma Inc. to develop and commercialise multiple novel products focussed on the US prescription cough cold market, as well as several programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.
Vernalis plc is listed on the Alternative Investment Market (AIM) in London. The Group’s US commercial operations are based in Berwyn PA. The fragment- and structure-based drug discovery staff are based in Cambridge, UK and the head office is based in Winnersh, UK.
